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Pathologic Quiz Case
A 93-Year-Old Woman With an Enlarged and Tender Left Breast
Jorge S. Reis-Filho, MD; Laura G. Fulford, MBBS; Alex Freeman, MD; Sunil R. Lakhani, MD, FRCPath
A93-year-old woman presented with a gradual onset ofan enlarging, tender, and erythematous left breast.
She had no other relevant history. Clinical examination
suggested an inflammatory carcinoma, along with an area
of diffuse thickening in the upper outer quadrant. She un-
derwent mammography, the results of which were unre-
markable, followed by a core biopsy of the thickened area.
Following this, she underwent a left mastectomy with ax-
illary dissection. Macroscopically, the specimen comprised
a disk of fibrofatty breast tissue, 150 3 80 3 50 mm, cov-
ered by a nipple-bearing ellipse of skin measuring 130 3
80 mm. On sectioning, the entire breast was diffusely pale
and firm, with a more distinct irregular, firm area that
measured 30 3 20 3 50 mm in the upper outer quadrant,
close to the deep margin.
Histologic examination revealed an extensive tumor, in-
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volving the entire breast, measuring 150 mm in maximum
size, and extending to the medial and lateral margins, the
dermis of the nipple skin, and within 1 mm of the deep
margin. The tumor was composed of single files of large
cells with focal targetoid growth around the normal breast
structures (Figure, A). The neoplastic cells contained
abundant foamy or finely granular pale pink cytoplasm
(Figure, A, inset, and Figure, B), with occasional intracy-
toplasmic lumina identified (Figure, B, inset). The nuclei
were uniform and round to oval; they had a fine chro-
matin pattern and a single prominent nucleolus. Mitotic
figures were 4 per 10 high-power fields. Neoplastic cells
were seen diffusely infiltrating through adipose tissue in
scattered areas, mimicking the appearances of fat necrosis
(Figure, C). Foci of lobular carcinoma in situ (LCIS) (Fig-
ure, A, arrows, and Figure, D, inset) admixed with the
invasive tumor and in surrounding breast parenchyma
were observed. No lymphovascular invasion was seen.
Three of 12 lymph nodes examined contained metastatic
carcinoma with morphologic findings similar to the pri-
mary tumor. Immunostaining for estrogen and progester-
one receptors was negative. Immunostaining for HER-2
was strongly and diffusely (31) positive. Gross cystic dis-
ease fluid protein 15 (GCDFP-15) (Figure, C, inset) and
androgen receptor were positive, whereas E-cadherin (Fig-
ure, D, and D inset), S100 protein, calretinin, a-inhibin,
and CD68 were negative in neoplastic cells.
What is your diagnosis?
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Pathologic Diagnosis: Histiocytoid Variant of Lobular
Breast Carcinoma
The term histiocytoid breast carcinoma (HBC) was first
coined by Hood et al1 in 1973. They described a group of
breast carcinomas, showing a predilection for metastasis to
the eyelid, composed of cells that resembled histiocytes
with small ‘‘inactive’’ nuclei and abundant vacuolated cy-
toplasm. The neoplastic cells stained with Mayer mucicar-
mine and were negative for oil red O. In 5 of 8 cases in
this series, the metastatic lesion presented before the pri-
mary carcinoma had been diagnosed. These lesions posed
difficulties in the differential diagnosis with other benign
lesions, such as xanthoma, xanthelasma, histiocytoma, and
granular cell tumor.1 Since this first report, several other
case reports and small series of HBC have been reported,
including a series of 13 cases under the heading myoblas-
tomatoid breast carcinoma.2
Some authors regard HBC as a variant of apocrine car-
cinoma2 or an apocrine variant of infiltrating lobular breast
carcinoma3–5 based on (1) the consistent expression of the
apocrine marker GCDFP-15; (2) the association with foci of
LCIS; (3) the presence of transitional areas between typical
LCIS and histiocytoid/apocrine LCIS; and (4) the identi-
fication of areas with single-cell filling and targetoid
growth pattern in bona fide cases of HBCs.4–6 These fea-
tures and the association of HBC with pleomorphic lobular
carcinoma may suggest that HBC is a variant of pleomor-
phic lobular carcinoma.6
In contrast, several lines of evidence suggest that HBC
is a morphological pattern that may be observed in ductal,
apocrine, and lobular breast carcinomas rather than a spe-
cific type of breast carcinoma per se.7 Recently, Gupta et
al7 described a series of 11 HBCs, in which 8 cases were
associated with LCIS. In that series, 10 of the 11 cases were
positive for the apocrine marker GCDFP-15, and 8 of these
cases lacked E-cadherin expression. Based on these find-
ings, the authors concluded that HBCs have an immuno-
phenotypical profile consistent with both ductal and lob-
ular differentiation and that the lack of specific and con-
sistent clinical findings, morphologic features, or immu-
nohistochemical profile warrants that histiocytoid
carcinoma should not be considered a special type of
breast cancer.
Despite the fact that it may not be a distinct entity, the
term HBC is useful to remind pathologists that these tu-
mors may be easily overlooked or misdiagnosed as benign
or inflammatory processes, including xanthomatous le-
sions and granular cell tumors,2 as well as other malignant
neoplasms, such as histiocytosis, histiocytic sarcoma, and
lipid-rich breast carcinoma. As noted in the present case,
when HBC is infiltrating through adipose tissue, it may
superficially simulate fat necrosis to the unwary.
Histiocytoid breast carcinoma may be distinguished
from histiocytic lesions by the presence of nuclear atypia
(albeit mild), the lack of histiocytic markers (CD68, HAM-
56, lysozyme, CD1a, and S100 protein), and the consistent
expression of markers of epithelial and apocrine differen-
tiation,2,4,6,7 namely, cytokeratins, epithelial membrane an-
tigen, and GCDFP-15. In the case of the lobular variant,
intracytoplasmic lumina and associated foci of LCIS in
most cases are helpful features for diagnosis. Granular cell
tumor may show a remarkable histologic similarity to
HBC2; however, the former expresses S100 protein, calre-
tinin, and a-inhibin8,9 and is negative for epithelial markers
and hormone receptors. Lipid-rich breast carcinoma is a
special type of breast carcinoma characterized by nests,
cords, and solid sheets of large polygonal cells, with abun-
dant foamy or multivacuolated lipid-rich cytoplasm, which
may confer a clear cell or lipoblast-like appearance to neo-
plastic cells.10 These tumors may be differentiated from
HBC by the distinctive morphologic features, lack of intra-
cytoplasmic lumina and mucin in lipid-rich breast carci-
nomas, and lack of lipids in HBC cells.1–6,10
Owing to the small number of cases published to date
and to the fact that HBC may not be a distinct entity, the
prognostic implications of histiocytoid morphologic fea-
tures in breast carcinomas remain unclear.
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